Author:
Kolou Malewe,Poda Armel,Diallo Zelica,Konou Esther,Dokpomiwa Tatiana,Zoungrana Jacques,Salou Mounerou,Mba-Tchounga Lionèle,Bigot André,Ouedraogo Abdoul-Salam,Bouyout-Akoutet Marielle,Ekouevi Didier K.,Eholie Serge P.
Abstract
Abstract
Background
The presence of the human leukocyte antigen HLA-B*57:01 is associated with the development of a hypersensitivity reaction to abacavir (ABC). Limited data exist on HLA-B*57:01 prevalence in individuals with HIV-1 in Africa. This study aimed to estimate HLA-B*57:01 prevalence in individuals with HIV-1 in West and Central Africa.
Methods
A cross-sectional study was conducted in four countries in West and central Africa (Burkina-Faso, Côte d’Ivoire, Gabon, and Togo) from January 2016 to February 2020 to determine the status of HLA-B*57:01 in adults with HIV-1. The presence of HLA-B*57:01 was determined by using Single Specific Primer-Polymerase Chain Reaction (SSP-PCR) in blood samples. Prevalence rates were stratified based on country.
Results
A total of 4016 (69.8% women) individuals with HIV were enrolled. Their median age was 45, and the interquartile range was 38–52. We included 500 (12.4%) patients in Burkina-Faso, 1453 (36.2%) in Côte d’Ivoire, 951 (23.7%) in Gabon, and 1112 (27.7%) in Togo. The overall HLA-B*57:01 prevalence was 0.1% [95% CI: 0.0–0.2%]. The prevalence of HLA-B*57:01 was similar according to the four countries. Only one case was reported in each country except Togo, with no cases.
Conclusions
HLA-B*57:01 prevalence is low in individuals with HIV in West and central Africa, and there is no difference among countries. This study does not confirm the utility of HLA-B*57:01 allele testing for abacavir use in this region.
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Aids Update 2020 – Seizing the moment: tackling entrenched inequalities to end epidemics. Geneva: UNAIDS; 2020. p. 40.
2. Parashar S, Collins AB, Montaner JS, Hogg RS, Milloy MJ. Reducing rates of preventable HIV/AIDS-associated mortality among people living with HIV who inject drugs. Curr Opin HIV AIDS. 2016;11(5):507–13. https://doi.org/10.1097/COH.0000000000000297.
3. Joint United Nations Programme on HIV/AIDS (UNAIDS). The gap report. Geneva: UNAIDS; 2014. p. 422. Available from: https://tinyurl.com/y5mr8ahf
4. Lee GQ, McCluskey S, Boum Y 2nd, Hunt PW, Martin JN, Bangsberg DR, et al. Brief report: should Abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa? J Acquir Immune Defic Syndr. 2017;76(2):188–92. https://doi.org/10.1097/QAI.0000000000001487.
5. Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, et al. Brief Report: Dolutegravir plus Abacavir/Lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the single randomized clinical trial. J Acquir Immune Defic Syndr. 2015; 70(5):515–519. doi: https://doi.org/10.1097/QAI.0000000000000790. Erratum in: J Acquir Immune Defic Syndr. 2016; 71(1):e33.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献